Adaptimmune Therapeutics plc (ADAP)

Name: Adaptimmune Therapeutics plc (ADAP) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Adaptimmune Therapeutics plc (ADAP)

Stock Card

$0.04

$0.01 (17.50%)

As on 03-Dec-2025 09:30EDT

Market cap

$15 Mln

Revenue (TTM)

$65 Mln

P/E Ratio

P/B Ratio

2.7

Div. Yield

0 %

Adaptimmune Therapeutics (ADAP) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 0.04 High: 0.05

52 Week Range

Low: 0.04 High: 0.74

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-13.4 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-1.7
Debt to Equity

-0.4
Book Value

$--
EPS

$-0.7
Face value

--
Shares outstanding

265,051,591

10 Years Aggregate

CFO

$-710.91 Mln

EBITDA

$-962.01 Mln

Net Profit

$-985.52 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Adaptimmune Therapeutics (ADAP)	-92.1	-16.7	-26.8	-94.2	-72.6	-60.8	-42.1
BSE Sensex^*	-9.1	-1.5	2.9	-3.6	5.9	6.0	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 03-Dec-2025 | *As on 01-Sep-2026 | #As on 26-Oct-2023

Company	2024	2023	2022	2021	2020	2019	2018
Adaptimmune Therapeutics (ADAP)	-31.9	-45.7	-61.1	-30.4	349.2	-79.1	-13.9
S&P Small-Cap 600	7.0	13.9	-17.4	25.3	9.6	20.9	-9.7
BSE Sensex	8.1	18.7	4.4	22.0	15.8	14.4	5.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Adaptimmune Therapeutics (ADAP)

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a... genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom. Read more

CEO, Principal Accounting Officer & Director

Mr. Adrian G. Rawcliffe
CEO, Principal Accounting Officer & Director

Mr. Adrian G. Rawcliffe
Headquarters

Abingdon
Website

https://www.adaptimmune.com

FAQs for Adaptimmune Therapeutics (ADAP)

What is the current share price of Adaptimmune Therapeutics plc (ADAP) Today?

The share price of Adaptimmune Therapeutics plc (ADAP) is $0.04 (NASDAQ) as of 03-Dec-2025 09:30 EDT. Adaptimmune Therapeutics plc (ADAP) has given a return of -72.62% in the last 3 years.

What is the current PB & PE ratio of Adaptimmune Therapeutics plc (ADAP)?

Since, TTM earnings of Adaptimmune Therapeutics plc (ADAP) is negative, P/E ratio is not available.
The P/B ratio of Adaptimmune Therapeutics plc (ADAP) is 2.68 times as on 03-Dec-2025, a 48 discount to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2024	-1.95	11.64
2023	-1.58	4.56
2022	-1.45	2.93
2021	-3.71	2.84
2020	-6.41	2.44

What is the 52 Week High and Low of Adaptimmune Therapeutics plc (ADAP)?

The 52-week high and low of Adaptimmune Therapeutics plc (ADAP) are Rs 0.74 and Rs 0.04 as of 01-Sep-2026.

What is the market cap of Adaptimmune Therapeutics plc (ADAP)?

Adaptimmune Therapeutics plc (ADAP) has a market capitalisation of $ 15 Mln as on 03-Dec-2025. As per SEBI classification, it is a Small Cap company.

Should I invest in Adaptimmune Therapeutics plc (ADAP)?

Before investing in Adaptimmune Therapeutics plc (ADAP), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.